Bao-Van has over 20 years of experience in Phase I-III global clinical development and operations. Prior to joining K36, Bao-Van was the clinical program lead for the lead r/r B-ALL CAR-T asset at Autolus Ltd, and spent 12 years at Amgen Inc working within the hematology/oncology portfolio, where she contributed to the BLA filing and initial marketing authorization of Blincyto® for r/r B-ALL.

​

Bao-Van has also worked in clinical and post-marketing programs in the CNS and GI/metabolic therapeutic areas, and has held roles of increasing responsibility in companies ranging in size from small start-up to large biotech and pharma.

​

Bao-Van received a BS in General Biology from the University of California, San Diego, and a MS in Biotechnology from the Johns Hopkins University.